We are live on ! Find out more
THRX

Theseus Pharmaceuticals, Inc. Common Stock
THRX

Delisted

THRX was delisted on the 13th of February, 2024.

Back to rankings

72 hedge funds and large institutions have $351M invested in Theseus Pharmaceuticals, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 22 increasing their positions, 11 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,250% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 2

113% more capital invested

Capital invested by funds: $165M → $351M (+$186M)

100% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 11

67% more funds holding in top 10

Funds holding in top 10: 3 → 5 (+2)

53% more funds holding

Funds holding: 47 → 72 (+25)

Holders
72
Holders Change
+25
Holders Change %
+53.19%
% of All Funds
1.15%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.08%
New
27
Increased
22
Reduced
11
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FFM
Fairmount Funds Management
Pennsylvania
+$18.3M
2
PBA
Paradigm Biocapital Advisors
New York
+$14.8M
3
FLSM
Frazier Life Sciences Management
California
+$8.34M
4
VA
VR Adviser
New York
+$7.56M
5
Citadel Advisors
Citadel Advisors
Florida
+$4.75M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$13.6M
2
WP
Woodline Partners
California
-$884K
3
BC
Boxer Capital
California
-$638K
4
OM
Opaleye Management
Massachusetts
-$460K
5
TCM
Tekla Capital Management
Massachusetts
-$245K
Name Holding Trade Value Shares
Change 		Change in
Stake
AllianceBernstein
26
AllianceBernstein
Tennessee
$1.37M +$1.51M +154,317 New
WP
27
Woodline Partners
California
$1.28M -$884K -90,022 -38%
Ensign Peak Advisors
28
Ensign Peak Advisors
Utah
$1.27M – – –
Northern Trust
29
Northern Trust
Illinois
$1.19M +$1.56K +159 +0.1%
DCM
30
DAFNA Capital Management
California
$1.16M +$483K +49,166 +60%
Renaissance Technologies
31
Renaissance Technologies
New York
$1.16M +$1.1M +111,800 +595%
ACM
32
Altium Capital Management
New York
$1M +$1.11M +112,614 New
Wellington Management Group
33
Wellington Management Group
Massachusetts
$991K +$1.1M +111,612 New
UOC
34
UBS O'Connor
Illinois
$983K +$1.09M +110,715 New
TD Asset Management
35
TD Asset Management
Ontario, Canada
$950K – – –
VCIM
36
Velan Capital Investment Management
Georgia
$888K +$981K +100,000 New
AAA
37
Affinity Asset Advisors
New York
$872K +$964K +98,221 New
Millennium Management
38
Millennium Management
New York
$711K +$786K +80,035 New
Manulife (Manufacturers Life Insurance)
39
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$708K +$232K +23,683 +42%
SSA
40
Schonfeld Strategic Advisors
New York
$696K +$769K +78,369 New
TCM
41
Tekla Capital Management
Massachusetts
$666K -$245K -25,000 -25%
Two Sigma Investments
42
Two Sigma Investments
New York
$658K +$559K +56,914 +331%
Bank of New York Mellon
43
Bank of New York Mellon
New York
$461K +$82.1K +8,369 +19%
Charles Schwab
44
Charles Schwab
California
$401K +$17.5K +1,784 +4%
Morgan Stanley
45
Morgan Stanley
New York
$372K +$298K +30,409 +265%
Hudson Bay Capital Management
46
Hudson Bay Capital Management
Connecticut
$311K +$344K +35,000 New
Two Sigma Advisers
47
Two Sigma Advisers
New York
$252K +$279K +28,400 New
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$229K +$8.05K +820 +3%
N
49
Nuveen
North Carolina
$194K – – –
CSS
50
Cubist Systematic Strategies
Connecticut
$161K +$177K +18,081 New
1
2
3

THRX Hedge Fund Activity: Q1 2023 in Review

72 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Theseus Pharmaceuticals, Inc. Common Stock (THRX) for Q1 2023, worth a combined $351M — up 113% from $165M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new THRX positions and 2 closed out — a net gain of 25 holders — while 22 added to existing stakes and 11 trimmed.

The largest buyer was Fairmount Funds Management, opening a new position worth an estimated $18.3M. The largest seller was Fidelity Investments, cutting an estimated $13.6M.

  • 72 institutional investors held Theseus Pharmaceuticals, Inc. Common Stock (THRX) as of Q1 2023, up from 47 in Q4 2022.
  • Funds reported $351M of Theseus Pharmaceuticals, Inc. Common Stock stock for Q1 2023, up 113% quarter-over-quarter.
  • 27 funds opened new Theseus Pharmaceuticals, Inc. Common Stock positions in Q1 2023 and 2 closed out, a net change of +25 holders.
  • The largest Theseus Pharmaceuticals, Inc. Common Stock buyer in Q1 2023 was Fairmount Funds Management, an estimated $18.3M added.
  • The largest Theseus Pharmaceuticals, Inc. Common Stock seller in Q1 2023 was Fidelity Investments, an estimated $13.6M sold.

Based on aggregated 13F filings for Q1 2023.